– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
- These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- ...
Medical genetics company Invitae is partnering with research program Simons Searchlight to analyze rare genetic neurodevelopmental disorders through data sharing. Invitae will share its longitudinal ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic ...
Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results